Table 1.
The regulatory role of ferroptosis related genes in ovarian cancer progression.
| Target | Mechanism | Function | Reference |
|---|---|---|---|
| FAC | Target Fe2+ and GPX4 | Induce ferroptosis and inhibit ovarian cancer | (126) |
| SCD1 | Target unsaturated fatty acyl chain | Induce ferroptosis and inhibit ovarian cancer | (127) |
| miR-424-5p | Target ACSL4/erastin/RSL3 | Induce ferroptosis and inhibit ovarian cancer | (128) |
| SPIO-serum | Target GPX4/xCT | Induce ferroptosis and inhibit ovarian cancer | (129) |
| PARP | Target SLC7A11 | Induce ferroptosis and inhibit ovarian cancer | (130) |
| SNAI2 | Target SLC7A11 | Induce ferroptosis and inhibit ovarian cancer | (131) |
| ADAMTS9-AS1 | Target miR-587/SLC7A11 | Inhibit ferroptosis and promote ovarian cancer | (132) |
| Sodium molybdate | Target NO/GSH | Induce ferroptosis and inhibit ovarian cancer | (133) |
| TAZ | Target ANGPTL4/NOX2 | Induce ferroptosis and reduce drug resistance | (134) |
| CBS | / | Inhibit ferroptosis and promote ovarian cancer | (135) |
| FZD7 | Target Tp63 | Induce ferroptosis and reduce platinum resistance | (136) |
| Erastin | Target ROS | Induce ferroptosis and inhibit ovarian cancer | (137) |
| GALNT14 | Target EGFR/mTOR | Induce ferroptosis and reduce platinum resistance | (138) |
| MAP30 | Target Ca2+ | Induce ferroptosis and reduce platinum resistance | (139) |
| Lidocaine | Target miR-382-5p/SLC7A11 | Induce ferroptosis and inhibit ovarian cancer | (140) |